Skip to content
Rizatriptan
Maxalt, Maxalt-mlt, Rizafilm (rizatriptan) is a small molecule pharmaceutical. Rizatriptan was first approved as Maxalt-mlt on 1998-06-29. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1A, and 5-hydroxytryptamine receptor 1E.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Maxalt, Maxalt-mlt, Rizafilm (generic drugs available since 2012-12-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rizatriptan benzoate
Tradename
Company
Number
Date
Products
RIZAFILMIntelgenxN-205394 RX2023-04-14
1 products, RLD, RS
MAXALT-MLTOrganonN-020865 RX1998-06-29
1 products, RLD, RS
MAXALTOrganonN-020864 RX1998-06-29
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
maxalt maxalt-mltNew Drug Application2021-06-01
rizatriptan benzoateANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
migraine disordersEFO_0003821D008881G43
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02C: Antimigraine preparations
— N02CC: Selective serotonin (5ht1) agonists
— N02CC04: Rizatriptan
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G4311194126
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine without auraD020326EFO_0005296G43.0——1——1
Migraine with auraD020325EFO_0005295G43.1——1——1
VertigoD014717H81.39—11——1
EpilepsyD004827EFO_0000474G40.9——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Post-traumatic headacheD051298G44.3————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRIZATRIPTAN
INNrizatriptan
Description
Rizatriptan is a member of tryptamines. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is functionally related to a N,N-dimethyltryptamine.
Classification
Small molecule
Drug classantimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12
Identifiers
PDB—
CAS-ID144034-80-0
RxCUI88014
ChEMBL IDCHEMBL905
ChEBI ID48273
PubChem CID5078
DrugBankDB00953
UNII ID51086HBW8G (ChemIDplus, GSRS)
Target
Agency Approved
HTR1B
HTR1B
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
3351
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Q4VAY7
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Alternate
HTR1F
HTR1F
HTR1A
HTR1A
HTR1E
HTR1E
Organism
Homo sapiens
Gene name
HTR1F
Gene synonyms
HTR1EL
NCBI Gene ID
3355
Protein name
5-hydroxytryptamine receptor 1F
Protein synonyms
5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled, Serotonin receptor 1F
Uniprot ID
P30939
Mouse ortholog
Htr1f (15557)
5-hydroxytryptamine receptor 1F (Q02284)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,255 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
298 adverse events reported
View more details